Amira Pharmaceuticals, Inc.
http://www.amirapharm.com/index.htm
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amira Pharmaceuticals, Inc.
A Year Of Paxlovid - Where Is The Licensed Generic?
A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.
A Year Of Paxlovid - Where Is The Licensed Generic?
It’s been a year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir. Scrip looks at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023 as Hetero's version becomes the first with WHO Prequalification while two Chinese and a Korean company wait in the wings.
Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches
Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.
'COVID Zero' Weakening Immune Systems? Flu Outbreaks Hit China
China reports flu outbreaks as COVID-19 cases decline, suggesting that population immunity may have been affected by the country's strict "COVID Zero" policies. The cost and availability of flu vaccines in the country are other policy factors playing into the situation.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice